首页> 美国卫生研究院文献>Journal of Gastric Cancer >Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

【2h】

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

机译：使用汇总的患者数据从二线雷珠单抗（REGARD和RAINBOW）的两项三期研究进行的胃癌总体生存期的预后因素分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer.

机译：目的确定患有疾病进展的患者在化疗期间或之后用于治疗晚期胃癌或胃食管连接（GEJ）癌症的生存率的基线预后因素。

著录项

期刊名称 Journal of Gastric Cancer
作者
Charles S. Fuchs; Kei Muro; Jiri Tomasek; Eric Van Cutsem; Jae Yong Cho; Sang-Cheul Oh; Howard Safran; György Bodoky; Ian Chau; Yasuhiro Shimada; Salah-Eddin Al-Batran; Rodolfo Passalacqua; Atsushi Ohtsu; Michael Emig; David Ferry; Kumari Chandrawansa; Yanzhi Hsu; Andreas Sashegyi; Astra M. Liepa; Hansjochen Wilke;
展开▼
作者单位

展开▼
年(卷),期 2017(17),2
年度 2017
页码 132–144
总页数 13
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Prognosis Stomach neoplasms Gastroesophageal junction Survival;

机译：预后;胃肿瘤;胃食管连接处;生存;

相似文献

外文文献
中文文献
专利

1. Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data [J] . Kei Muro, Min-Hua Jen, Rebecca Cheng Cancer Management and Research . 2019,第SpecaNoaA期

机译：雷莫昔单抗和紫杉醇疗法对腹水患者转移性胃癌或结节性腺癌的二线治疗是否有益？ RAINBOW 3期试验数据分析
2. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study [J] . Van Cutsem E., Muro K., Cunningham D., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第期

机译：来自彩虹晚期胃癌患者的二线Ramucirumab的生物标志物分析，全球，随机，双盲，第3期研究
3. Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer [J] . Chung Hyun Cheol, Kok Victor C., Cheng Rebecca, Asia-Pacific journal of clinical oncology . 2018,第3期

机译：东亚患者的亚群分析 - AICUCILUMAB的试验，晚期胃癌最佳支持性护理
4. Application of artificial neural network and multiple linear regression models for predicting survival time of patients with non-small cell cancer using multiple prognostic factors including FDG-PET measurements [C] . Pu Yonglin, Baad Michael J., Jiang Yulei, International Joint Conference on Neural Networks . 2014

机译：人工神经网络和多元线性回归模型在包括FDG-PET测量在内的多种预后因素预测非小细胞癌患者生存时间中的应用
5. Analysis of prognostic factors for the development of metastases and survival in renal cell carcinoma patients [D] . Cheng, Jed-Sian 2008

机译：肾细胞癌患者转移和存活的预后因素分析
6. Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data [O] . Kei Muro, Min-Hua Jen, Rebecca Cheng 2019

机译：雷莫昔单抗和紫杉醇疗法对腹水患者转移性胃癌或结节性腺癌的二线治疗是否有益？ RAINBOW 3期试验数据分析
7. Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD , RAINBOW , and RAINFALL Phase III Studies [O] . Wasat Mansoor, Eric J. Roeland, Aafia Chaudhry, 2021

机译：早期减肥作为晚期胃癌患者的预后因素：分析彩虹和降雨期III研究

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

摘要

著录项

相似文献

相关主题

期刊订阅